Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2136988 | Leukemia Research | 2014 | 6 Pages |
Abstract
Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p = 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michael E. O’Dwyer, Ronan Swords, Arnon Nagler, Mary Frances McMullin, Philipp D. le Coutre, Stephen E. Langabeer, Alberto Alvarez-Iglesias, Hongxin Fan, Richard C. Woodman, Francis J. Giles, Eibhlin Conneally,